Meeting Banner
Abstract #4978

Anti-angiogenic treatment alters stiffness of glioblastoma in an orthotopic mouse model

Katharina Schregel1,2,3, Michal Oskar Nowicki4, Miklos Palotai2,3, Navid Nazari5, Rachel Zane4, Ralph Sinkus6, Sean Lawler3,4, and Samuel Patz2,3

1Institute of Neuroradiology, University Medical Center Goettingen, Goettingen, Germany, 2Department of Radiology, Brigham and Women's Hospital, Boston, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States, 5Department of Biomedical Engineering, Boston University, Boston, MA, United States, 6Department of Radiological Imaging, Imaging Sciences & Biomedical Engineering Division, King's College London, London, United Kingdom

Glioblastoma (GBM) is the most common malignant brain tumor. As it is highly vascularized, anti-angiogenic treatment strategies have been tested. Such treatment hinders radiological tumor monitoring. Here, we probed the potential of magnetic resonance elastography (MRE) to evaluate GBM treated with anti-angiogenic therapy. GBM was orthotopically implanted in 10 nude mice, of which 5 were treated with B20 anti-VEGF antibody. MRI and MRE were performed repeatedly and brains were harvested for histology afterwards. Anti-angiogenic treatment slowed tumor growth, affected contrast-enhancement and slowed down tumor softening. The phase angle Y expressing the solid/liquid ratio appeared to indicate tumor progression.

This abstract and the presentation materials are available to members only; a login is required.

Join Here